Journal article
Jinming Yang, Amrendra Kumar, A. Vilgelm, Sheau-Chiann Chen, G. Ayers, S. Novitskiy, S. Joyce, A. Richmond
Cancer Immunology Research, 2018
Cancer Immunology Research, 2018
Semantic Scholar
DOI
PubMed
Cite
Cite
APA
Click to copy
Yang, J., Kumar, A., Vilgelm, A., Chen, S.-C., Ayers, G., Novitskiy, S., … Richmond, A. (2018). Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms. Cancer Immunology Research.
Chicago/Turabian
Click to copy
Yang, Jinming, Amrendra Kumar, A. Vilgelm, Sheau-Chiann Chen, G. Ayers, S. Novitskiy, S. Joyce, and A. Richmond. “Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms.” Cancer Immunology Research (2018).
MLA
Click to copy
Yang, Jinming, et al. “Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms.” Cancer Immunology Research, 2018.
BibTeX Click to copy
@article{jinming2018a,
title = {Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms},
year = {2018},
journal = {Cancer Immunology Research},
author = {Yang, Jinming and Kumar, Amrendra and Vilgelm, A. and Chen, Sheau-Chiann and Ayers, G. and Novitskiy, S. and Joyce, S. and Richmond, A.}
}
Abstract
NK-cell antitumor activity is enhanced by myeloid-CXCR4 deletion, revealing a pathway by which this receptor may contribute to tumor surveillance suppression and promotion of metastasis. This pathway provides a rationale for the clinical application of CXCR4 antagonists. The chemokine receptor, CXCR4, is involved in cancer growth, invasion, and metastasis. Several promising CXCR4 antagonists have been shown to halt tumor metastasis in preclinical studies, and clinical trials evaluating the effectiveness of these agents in patients with cancer are ongoing. However, the impact of targeting CXCR4 specifically on immune cells is not clear. Here, we demonstrate that genetic deletion of CXCR4 in myeloid cells (CXCR4MyeΔ/Δ) enhances the antitumor immune response, resulting in significantly reduced melanoma tumor growth. Moreover, CXCR4MyeΔ/Δ mice exhibited slowed tumor progression compared with CXCR4WT mice in an inducible melanocyte BrafV600E/Pten−/− mouse model. The percentage of Fas ligand (FasL)–expressing myeloid cells was reduced in CXCR4MyeΔ/Δ mice as compared with myeloid cells from CXCR4WT mice. In contrast, there was an increased percentage of natural killer (NK) cells expressing FasL in tumors growing in CXCR4MyeΔ/Δ mice. NK cells from CXCR4MyeΔ/Δ mice also exhibited increased tumor cell killing capacity in vivo, based on clearance of NK-sensitive Yac-1 cells. NK cell–mediated killing of Yac-1 cells occurred in a FasL-dependent manner, which was partially dependent upon the presence of CXCR4MyeΔ/Δ neutrophils. Furthermore, enhanced NK cell activity in CXCR4MyeΔ/Δ mice was also associated with increased production of IL18 by specific leukocyte subpopulations. These data suggest that CXCR4-mediated signals from myeloid cells suppress NK cell–mediated tumor surveillance and thereby enhance tumor growth. Systemic delivery of a peptide antagonist of CXCR4 to tumor-bearing CXCR4WT mice resulted in enhanced NK-cell activation and reduced tumor growth, supporting potential clinical implications for CXCR4 antagonism in some cancers. Cancer Immunol Res; 6(10); 1186–98. ©2018 AACR.
